Australia: TGA cancels Prexige registration over liver risks

08/12/2007 | MarketWatch

Australia's Therapeutic Goods Administration moved Saturday to cancel the registration of Novartis AG's pain drug Prexige after reports of liver damage risks surfaced. Prexige, a Cox-2 inhibitor similar to Vioxx, reportedly caused liver-related adverse reactions in the eight cases received by the TGA.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC